ALLERGY THERAPEUTICS PLC

AGM Information • Mar 8, 2024

National Storage Mechanism | Additional information

RNS Number : 2043G

Allergy Therapeutics PLC

08 March 2024

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

8 March 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2023 Annual General Meeting ("AGM") held today were duly passed by shareholders by way of poll vote.

Resolutions 1 to 11 (inclusive) were proposed as ordinary resolutions and resolutions 12 to 14 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.

Resolution	For:	%age	Against:	%age	Total Votes Cast	Withheld
1. Approval of 2023 Accounts	4,454,427,655	100.00%	100,000	0.00%	4,454,529,660	2,005
2. Approval of Directors' Remuneration Report	4,440,353,568	99.68%	14,174,087	0.32%	4,454,529,660	2,005
3. To re-elect Mary Tavener as a Director	4,454,239,121	99.99%	278,279	0.01%	4,454,529,660	12,260
4. To re-elect Tunde Otulana as a Director	4,454,384,117	100.00%	133,283	0.00%	4,454,529,660	12,260
5. To re-elect Manuel Llobet as a Director	4,454,284,117	99.99%	233,283	0.01%	4,454,529,660	12,260
6. To re-elect Cheryl MacDiarmid as a Director	4,454,384,117	100.00%	133,283	0.00%	4,454,529,660	12,260
7. To re-elect Peter Jensen O.B.E. as a Director	4,440,494,882	99.69%	14,015,154	0.31%	4,454,529,660	19,624
8. To re-appoint BDO LLP as auditors of the Company	4,454,306,655	100.00%	221,000	0.00%	4,454,529,660	2,005
9. To authorise the Directors to agree the Auditors remuneration	4,454,415,654	100.00%	108,001	0.00%	4,454,529,660	6,005
10. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551)	4,454,236,175	99.99%	291,480	0.01%	4,454,529,660	2,005
11. Authority to issue warrants	4,440,359,504	99.68%	14,168,151	0.32%	4,454,529,660	2,005
12. Special Resolution:   To authorise the Directors to allot equity securities for cash without first being required to offer such shares to existing shareholders for a period expiring at the conclusion of the next annual general meeting of the Company or 31 December 2024, whichever occurs first.	4,440,458,304	99.68%	14,069,351	0.32%	4,454,529,660	2,005
13. Special Resolution: To authorise the Directors to allot equity securities and/or sell treasury shares for cash without first being required to offer such securities to existing shareholders	4,440,458,304	99.68%	14,069,351	0.32%	4,454,529,660	2,005
14. Special Resolution: Disapplication of pre-emption rights in relation to the Warrants	4,440,428,445	99.68%	14,095,210	0.32%	4,454,529,660	6,005

- ENDS -

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSWFDAELSELD